ZLAB earnings analysis
What we found in ZLAB's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Zai Lab reported a disappointing Q1 2026 with revenue of $99.6 million, falling short of expectations by $8.85 million and reflecting a 10% year-over-year decline, primarily due to a significant drop in ZEJULA sales. The net loss increased to $51 million from $48.4 million a year ago, indicating continued challenges in achieving profitability amidst rising operational costs and shifting market dynamics.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Decline
- Total revenue of $99.6 million was down 10% year-over-year from $105.7 million.
- Increased Net Loss
- Net loss for Q1 2026 increased to $51.0 million, compared to $48.4 million in Q1 2025.
- Product Revenue Drop in ZEJULA
- Sales from ZEJULA decreased by 39%, from $49.5 million to $30 million.
- Higher Collaboration Revenue
- Collaboration revenue surged by 384%, from $837,000 to $4.1 million.
- R&D Expense Increase
- Research and development expenses increased by 8% to $65.6 million from $60.7 million.
- Foreign Currency Gains
- Foreign currency gains increased substantially to $14.8 million from $0.65 million a year earlier.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Sales Volume Decrease Risks
- Sales for ZEJULA decreased significantly by 39%, indicating market challenges.
- Operational Losses Increase
- Loss from operations rose 23% to $69.4 million from $56.3 million.
- Cash Flow Concerns
- Net cash used in operating activities was $11.9 million, down from $61.7 million the prior year, indicating ongoing cash pressure despite improvements.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.05
- Segment
- Product Revenue: $95.6M
- Segment
- Collaboration Revenue: $4.1M
What they said about what is next.
No specific forward guidance provided.
The filing reads worse than the one before it.
What came before.
- 10-K · February 26, 2026
- Zai Lab positions itself as a commercial-stage, China-focused global biopharma with seven launched programs in Greater China and a strategy to accelerate medicines to patients, expand its pipeline, and drive commercial…
- 10-Q · November 6, 2025
- Zai Lab reported Q3 2025 total revenues of $116,095,000 (up from $102,265,000 in Q3 2024) and a GAAP net loss of $35,963,000 (loss per share $0.03). Operating loss narrowed to $(48,822,000) from $(67,853,000)…
- 10-Q · May 8, 2025
- Zai Lab reported Q1 2025 revenue of $106.487M and a GAAP net loss of $48.438M (loss per share $0.04). Revenue and gross margin improved year-over-year, operating loss and cash burn narrowed vs. Q1 2024, while working…
- 10-K · February 27, 2025
- Zai Lab is a commercial-stage, China-focused biopharma with seven commercial programs and an explicit strategy to accelerate medicines to patients, expand its pipeline, and improve commercial execution. The 10-K…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ZLAB makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever